Encompass Health (NYSE:EHC) Releases Earnings Results, Beats Expectations By $0.19 EPS

Encompass Health (NYSE:EHC - Get Free Report) released its quarterly earnings results on Wednesday. The company reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.93 by $0.19, Briefing.com reports. The firm had revenue of $1.32 billion during the quarter, compared to analysts' expectations of $1.27 billion. Encompass Health had a return on equity of 17.69% and a net margin of 7.33%. Encompass Health's quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 EPS. Encompass Health updated its FY24 guidance to $3.86-4.11 EPS.

Encompass Health Trading Down 0.1 %

NYSE:EHC traded down $0.06 during trading hours on Thursday, hitting $82.74. 1,488,277 shares of the stock were exchanged, compared to its average volume of 671,911. The company has a quick ratio of 1.28, a current ratio of 1.28 and a debt-to-equity ratio of 1.19. The company's 50 day moving average is $77.89 and its two-hundred day moving average is $70.67. Encompass Health has a twelve month low of $57.55 and a twelve month high of $85.84. The company has a market capitalization of $8.29 billion, a P/E ratio of 23.69, a price-to-earnings-growth ratio of 1.53 and a beta of 0.94.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Monday, April 1st were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date was Thursday, March 28th. Encompass Health's payout ratio is 17.29%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Barclays upped their price target on Encompass Health from $101.00 to $108.00 and gave the company an "overweight" rating in a research report on Thursday. Truist Financial increased their price target on Encompass Health from $82.00 to $86.00 and gave the stock a "buy" rating in a research note on Friday, February 9th. Mizuho increased their price target on Encompass Health from $93.00 to $95.00 and gave the stock a "buy" rating in a research note on Thursday. William Blair reissued an "outperform" rating on shares of Encompass Health in a research note on Wednesday, February 7th. Finally, Stephens reissued an "overweight" rating and issued a $85.00 price target on shares of Encompass Health in a research note on Tuesday, January 16th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Encompass Health presently has a consensus rating of "Buy" and a consensus price target of $85.44.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.